BNT162b2 Vaccine Booster and Mortality Due to Covid-19.

Ronen ArbelAriel HammermanRuslan SergienkoMichael FrigerAlon PeretzDoron NetzerShlomit Yaron

Published in: The New England journal of medicine (2021)

Participants who received a booster at least 5 months after a second dose of BNT162b2 had 90% lower mortality due to Covid-19 than participants who did not receive a booster.

Keyphrases

coronavirus disease
sars cov
cardiovascular events
risk factors
respiratory syndrome coronavirus